Introduction {#S0001}
============

Alveolar soft part sarcoma (ASPS) is a rare, mostly chemo-resistant soft tissue sarcoma (STS) subtype characterized by the unbalanced translocation t(X; 17) (p11.2; q25.3), which results in the ASPACR1-TFE3 fusion gene. ASPS accounts for only 0.5--1% of all STS.[@CIT0001],[@CIT0002] A paradoxical high metastatic rate,[@CIT0003],[@CIT0004] is characterized by metastasis to lungs, lymph nodes and bone.[@CIT0001],[@CIT0005],[@CIT0006] ASPS usually show an indolent course and occurs in the lower extremities, especially in the lower limbs. Some patients already show distant metastasis and invasion at initial visiting.[@CIT0001],[@CIT0007] These patients have a 5-year survival rate of only 20%, compared with 71% in patients with localized disease[@CIT0008] Metastasis, together with large tumor size, older age, and a truncal primary site, are independent prognostic factors for ASPS[@CIT0007]

Complete excision of ASPS is the most common curative treatment, while radiotherapy may be recommended in patients without an R~0~ resection.[@CIT0001],[@CIT0009] The National Comprehensive Cancer Network (NCCN) suggests chemotherapy for advanced, inoperable and/or metastatic STS, but advanced or metastatic ASPS is generally not sensitive to conventional cytotoxic chemotherapy.[@CIT0001],[@CIT0005],[@CIT0008] The key role of pathological angiogenesis in STS progression, invasion and metastasis,[@CIT0010] and upregulation of angiogenic and metastatic targets, such as vascular endothelial growth factor (VEGF) and c-Met, were revealed in ASPS by transcriptomic analysis[@CIT0005] In addition, ASPS is highly vascular, so the use of angiogenesis inhibitors may be effective for the treatment of metastatic ASPS. A number angiogenesis targeting agents have been used therapeutically for ASPS, including pazopanib,[@CIT0011] crizotinib,[@CIT0012] sorafenib[@CIT0013] and anlotinib[@CIT0014]

Apatinib is a novel tyrosine kinase receptor inhibitor that selectively competes for the vascular endothelial growth factor receptor 2 (VEGFR-2) ATP binding site, blocking downstream signaling and inhibiting tumor angiogenesis[@CIT0015] Apatinib improves progression-free survival (PFS) and overall survival (OS), in patients with advanced gastric cancer[@CIT0016] It is considered to be useful for systemic treatment in patients with metastatic STS, including synovial sarcoma, undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor.[@CIT0017],[@CIT0018]

No prior case series has reported the efficacy and safety of apatinib in metastatic ASPS. Thus, this study aimed to investigate the efficacy of apatinib, a specific VEGFR-2 inhibitor, in patients with metastatic ASPS. We conducted a retrospective cohort study to evaluate the association of anti-angiogenesis related adverse events (AEs) with clinical outcomes in patients with metastatic ASPS, and report data from a total of 6 patients treated with apatinib. Our study describes the efficacy and safety of apatinib in patients with metastatic ASPS who were treated at the Department of Orthopaedics of the West China Hospital.

Methods {#S0002}
=======

Eligibility criteria {#S0002-S2001}
--------------------

The study was conducted retrospectively for patients treated from February 1, 2015, to July 18, 2018. The inclusion criteria included the following: 1) histologically proven ASPS; 2) initial treatment in the Department of Orthopedics of the West China Hospital; 3) patients with a diagnosis of metastatic ASPS deemed incurable by conventional surgery, radiotherapy or systemic therapy; 4) measurable lesions according to the Response Evaluation Criteria for Solid Tumors (RECIST)[@CIT0019] 5) no previous malignancy; 6) centrally reviewed pathology materials (representative slides).

Treatment methods {#S0002-S2002}
-----------------

Apatinib was orally administered at dose of 500 mg per day in the selected patients(500 mg once or 250 mg twice daily)[@CIT0018] One treatment cycle was continuous for 28 days until progression or toxicity. Dose-limiting toxicity (DLT) was defined as possible or definite drug-related grade 3 to grade 4 toxic response. This study was performed according to the principles of the Declaration of Helsinki and the Institutional Review Board of Sichuan University West China Hospital. Written informed consent was obtained from all patients prior to treatment. The study protocol followed all appropriate guidelines according to the Declaration of Helsinki.

Evaluation of efficacy and safety {#S0002-S2003}
---------------------------------

In our retrospective study, response to treatment was assessed according to RECIST (version 1.1) guidelines. We were mainly concerned with documenting disease control rate (DCR), defined as the percentage of patients achieving a complete response (CR), partial response (PR) and stable disease (SD); objective response rate (ORR) defined as the percentage of patients showing CR and PR; PFS, and OS. Treatment efficacy was evaluated by computed tomography (CT) for lung metastasis and magnetic resonance imaging (MRI) for the primary tumor. Additionally, adverse events (AEs) encountered were recorded on the basis of frequency and severity of events assessed according to the Common Terminology Criteria for Adverse Events.

Statistical analysis {#S0002-S2004}
--------------------

Kaplan-Meier survival curves were used for PFS and OS estimation. Data analyses were performed using SPSS 20.0 software (IBM Corporation, Armonk, NY, USA). PFS was defined as the time from the date of diagnosis to the date of progression or last follow up. OS was defined as the time from the date of diagnosis to death or last follow up. Significance (*P*\<0.05, two-tailed) was assessed by log-rank tests for PFS and OS.

Results {#S0003}
=======

Patient characteristics {#S0003-S2001}
-----------------------

From February 1, 2015, to July 18, 2018, six consecutive patients were enrolled. All pathology materials were confirmed at West China Hospital. Patient clinical characteristics are shown in [Tables 1](#T0001){ref-type="table"} and [3](#T0003){ref-type="table"}. Median age was 26.5 (range, 17--32) years, and median follow-up time was 20.6 (range, 12.43--34.13) months. Before treatment with apatinib, one patient (16.7%) had lung metastasis occurred one month after surgery, but disease progressed after one circle chemotherapy (gemcitabine 1000 mg/m^2^ d~1,\ 8~ and docetaxel 75 mg/m^2^ d~8~). So apatinib was administered as the second-line therapy for this patient. The other five (83.3%) patients had lung metastasis, deemed incurable by local or systemic therapy, at initial presentation. Thus apatinib was administered as first-line therapy in these patients. All the six patients were evaluated by physicians at our clinic on a monthly basis and chest CT and MRI of tumor lesions at the primary site were routinely performed.Table 1Patient characteristicsCharacteristicsNumber of patients (percentage & range)Sex Male5 (83.3) Female1 (16.7)Age (years) Median26.5 (17--32) 10--171 (16.7) \>175 (83.3)Metastatic site Lung only6 (100)Number of previous treatment lines 15 (83.3) 21 (16.7)Primary tumor site Extremities4 (83.3) Trunk2 (16.7)Primary tumor size \>5cm5 (83.3) \<5cm1 (16.7) Table 2Patients' clinical evaluationsclinical evaluationNumber of patients (percentage & range)N (missing)6 (0)CR1 (16.67%)PR5 (83.33%)SD0 (0.00%)PD0 (0.00%)ORR (95% CI)100.00 (54.07--100.00)DCR (95% CI)100.00 (54.07--100.00)[^2] Table 3Clinical characteristics of 6 patients with metastatic ASPS treated with apatinibPatientsGenderAge (years)ECOG PSPrimary siteMetastatic siteSurgery before apatinibTreatment lineInitial does (mg)Overall survival (m)Progression free survival (m)Medication time (m)Duration of response (m)Best response1Male261Left thighLungYes2500NANA22.8NACR2Male321Right thighLungNo1500NANA12.8NAPR3Male291PelvisLung,No1500NA18.518.917.4PR4Female272Right thighLungNo1500NA6.24.514.7PR5Male222Right shoulderLungNo1500NA12.212.29.6PR6Male171Right thighLungNo1500NANA5.8NAPR[^3]

Efficacy {#S0003-S2002}
--------

By the last scheduled visit, all the patients were alive. The best response to apatinib by RECIST was: 1 CR, 5 PR ([Figure 1](#F0001){ref-type="fig"}). The ORR and DCR were similarly 100.00(95% CI, 54.07--100.00) ([Tables 2](#T0002){ref-type="table"} and [3](#T0003){ref-type="table"}). The median PFS was 18.53 months (95% CI, 12.23-NE). However, median OS has not been reached. The 12- and 24-month OS rates were 100.0% each ([Figure 2](#F0002){ref-type="fig"}). And the 12-month and 24-month PFS rates were 100.00 (95%CI, 100.00--100.00) and 50.00% (95%CI 11.09--80.37), respectively ([Figure 3](#F0003){ref-type="fig"}).Figure 1Kaplan-Meier estimates of progression free survival for all patients.Figure 2Kaplan-Meier estimates of progression free survival for all patients.Figure 3The patient with best response of PR. Chest CT of different periods are shown the nature of radiological response (\[**A**\] before apatinib treatment; \[**B**\] 1 month after targeted therapy; \[**C**\] 3 months after targeted therapy; \[**D**\] 7 months after targeted therapy).

Safety and toxicity {#S0003-S2003}
-------------------

No adverse events were noted in any of the patients, and treatment continued uninterrupted. No new or unexpected AEs were noted ([Table 4](#T0004){ref-type="table"}). Adverse events occurring in more than 10% of all the patients included the following: gastrointestinal discomfort (4/6\[66.7%\]), hair hypopigmentation (4/6\[66.7%\]) and hand-foot skin reaction (3/6\[50.0%\]). All adverse reactions were mild (grade 1 or 2) and were easily controlled. No treatment-related death occurred, and no dose reductions were needed.Table 4Adverse eventsTotal, NGradeAE123--4Gastrointestinal discomfort^a^4310Hair hypopigmentation4220Hand-foot skin reaction31\<bold\>2\</bold\>0Anorexia2200Oral ulcers2200Fatigue2110Wound-healing problems1100Proteinuria1100Hypothyroidism1020Hypertension1100[^4]

Discussion {#S0004}
==========

Metastatic ASPS is resistant to conventional systemic therapies associated with microphthalmia transcription factor (MiT).[@CIT0001],[@CIT0008] The MiT gene family includes TFE3, TFEB, TFEC, and MiTF[@CIT0020] ASPSCR1-TFE3 causes MET autophosphorylation and activation of downstream signaling such as PI3K/AKT and MAPK[@CIT0021] These pathways drive pathological angiogenesis and tumor metastasis. Antiangiogenic strategies are emphasized for interrupting these pathways in patients with metastatic ASPS.

Several reports have revealed robust expression of angiogenesis in ASPS associated with vascular endothelial growth factor receptor (VEGFR)1, VEGFR2, VEGFR3, epidermal growth factor (EGF), MET, RET, platelet-derived growth factor (PDGF)B, PDGFRB and innate immunity-related receptors such as toll-like receptors (TLR)2 and TLR9.[@CIT0004],[@CIT0022]

VEGF is one of the central drivers for angiogenesis,[@CIT0023] and VEGFR-2 is the key mediator of recognized VEGF-induced phenotypes[@CIT0024] In vivo, the efficacy of antiangiogenic agents for the treatment of ASPS has been confirmed[@CIT0025] Several clinical trials reported that anti-angiogenic agents, such as pazopanib,[@CIT0011] crizotinib,[@CIT0012] sorafenib,[@CIT0013] anlotinib,[@CIT0014] sunitinib[@CIT0026] and cediranib,[@CIT0013] can be effective in patients with ASPS results of these reports are summarized in [Table 5](#T0005){ref-type="table"}. For advanced or metastatic ASPS, anti-angiogenic agents were often administered as first- or second-line treatment. Especially, a single patient may have received multiple targeted agents concurrently after disease progression[@CIT0013] Rates of tumor growth and metastasis have been variable, and clinical benefits are difficult to assess. No severe adverse effects were reported, also no patients were withdrawn from treatment because of AEs. Overall, 11.0% of patients (9/82) had PR as the best response. Maximum median PFS was 24.5 months.Table 5anti-angiogenic agents for advanced or metastatic ASPSDrug (references)No. of patientsAge (years)Tumor site\
(primary/metastasis)Best responseResponse duration (month)Objective response\
rate (%)Anlotinib[@CIT0014]13\>18NANAMedian PFS 21.0\
Median OS NA\
24m OSR 92%46.0Cediranib[@CIT0013]212 and 17Shoulder/lung, brain\
Calf/lungOne SD10.50Crizotinib[@CIT0012]45Median 30 (16--69)NATwo PRMedian PFS 8.1\
Median OS NA\
24m OSR 81.2%4.4PazopanibRicardo J.[@CIT0027]418--29Trunk and extremities/lungOne SDMedian PFS 24.5\
Median OS NA0Funakoshi et al[@CIT0028]111Thigh/lungOne PR8100Sorafenib[@CIT0013]212 and 17Shoulder/lung, brain\
Calf/lungOne PR2250.0Sunitinb[@CIT0026]15Median 32Trunk and extremities/\
pelvis and lungSix PRMedian PFS 19\
Median OS NA40.0[^5]

Apatinib, a specific VEGFR-2 inhibitor, was licensed by the China Food and Drug Administration (CFDA) for the treatment of advanced/metastatic gastric cancer and adenocarcinomas of the gastroesophageal junction in 2014. Its anti-cancer effects have been reported for a broad range of malignancies, such as osteosarcoma, rhabdomyosarcoma, synovial sarcoma and alveolar soft part sarcoma.[@CIT0018],[@CIT0029]

The main objective of this study was to evaluate the activity and safety of apatinib in metastatic ASPS. Only one study has evaluated the response of ASPS to apatinib. Xie et al reported results of apatinib use for advanced sarcoma. Three patients with advanced ASPS were administered apatinib as the second-line treatment after poor response to cytotoxic chemotherapy (gemcitabine 1000 mg/m^2^ d~1,\ 8~ and docetaxel 75 mg/m^2^ d~8~). Two patients had PR with an average duration of response of 7.4 months[@CIT0018] Apatinib was administered as the first-line treatment option for 5 patients and the second-line for one patient in our study, with the notable result of one CR and five PR. Median PFS was 18.53 months (95% CI, 12.23-NE), a 24-month OS rate was 100.0%, and the 24-month PFS rate was 50.0%. Since three of our patients were assessed as PD, the duration of response (DR) of patients could be partly evaluated ([Table 3](#T0003){ref-type="table"}). Patient (No.6) with the best response (CP), showed poor response to conventional chemotherapy ([Figure 4](#F0004){ref-type="fig"}), and apatinib was used as a second-line treatment. He discontinued apatinib treatment after 5.8 months of treatment due to its economic burden. At the last follow-up, a recurrence of lung metastasis was found. Compared with the initial CT of the chest, response to treatment was PR. We conclude that the main difference between the two reports is chemotherapy. In ASPS, a larger tumor reflects a longer disease history and metastasis rate rather than tumor growth rate and biological aggressiveness.[@CIT0001] We speculate that the metabolism of tumor cells might differ ASPS and other STSs. Further, conventional chemotherapy agents primarily act on DNA or RNA in the cell cycle. Tumor cells are selected for insensitive chemotherapy, which contributes to the formation of chemotherapy-resistant ASPS. Thus, cytotoxic chemotherapy, including doxorubicin, gemcitabine and docetaxel, shows little efficacy.Figure 4The patient with best response of CR. CT of chest are shown before and after treatment.

Previously, our institution used gemcitabine and docetaxel prior to targeted therapy for patients with metastatic ASPS, because of the central role of chemotherapy in systemic treatment according to the NCCN guidelines. However, in recent years, we changed our therapeutic strategy. First, since 2012, the NCCN guideline suggested sunitinib as a systemic agent for ASPS. Second, the efficacy of antiangiogenic drugs, especially sunitinib, was confirmed in patients with advanced or metastatic ASPS.[@CIT0014],[@CIT0022],[@CIT0026] Third, apatinib has been reported as the first-line treatment for off-label use in advanced or metastatic STS.[@CIT0018],[@CIT0030] Finally, CR occurred in a patient No.6 after two treatment cycles of apatinib. Subsequently, we administered apatinib as the first-line treatment in two patients with metastatic ASPS, and both of them showed PR. In general, for first-line treatment, Van et al suggested a 6-month PFR of \>30--56% and for second-line therapy a 3-month PFR of \>40% as an indicator of promising activity[@CIT0031] Therefore, the results of our study, indicate that apatinib is an adequate choice for first-line treatment for patients with metastatic ASPS.

For the AEs, the most common toxicities previously reported are hand-foot skin reaction, fatigue and hypertension in the previous reports[@CIT0029] Importantly, no patient had to discontinue apatinib because of AEs. The most common AEs in our study were gastrointestinal discomfort (4/6\[66.7%\]), hair hypopigmentation (4/6\[66.7%\]) and hand-foot skin reaction (3/6\[50.0%\]). Only one of our patients had hypertension and two complained of fatigue. No grade 3/4 toxicities were observed. Interestingly, previous studies reported that patients with grade 3/4 toxicities had a longer PFS than those without the AE, especially for patients with hypertension and hand-foot skin reactions[@CIT0032] Similar results were not found in our study, and we speculate the difference lies in the indolent behavior of ASPS.

Our study has some limitations. First, as a retrospective study, inclusion criteria utilized here were not as rigorous as those employed in formal prospective trials. We only enrolled six patients with the median follow-up time of 20.6 months. Further, it is still unclear when apatinib treatment should be stopped. Second, in spite of the encouraging results, our study is limited to clinical evaluation, lacking relevant molecular biology detection. For example, MET gene expression was not assessed[@CIT0012] Third, although apatinib is known as a specific VEGFR-2 inhibitor, there remains a question whether apatinib also suppresses the activity of other factors such as EGF, PDGFRα/β, Aurora-B, Ret, c-FMS, and c-Kit.

Conclusion {#S0005}
==========

Our study provides the first evidence of the efficacy and safety of apatinib in patients with metastatic ASPS as a first-line medical option. Though the results are notable, drug resistance and AEs associated with apatinib remain controversial. Further multicenter randomized controlled trials with longer follow-up time will be required to completely characterize the efficacy and safety of apatinib in metastatic ASPS.
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